BariatricNurseD said:

Orforglipron is the more interesting oral story because it is not a peptide at all.

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

That is the short version; the long version is somebody else's post.

One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Dr.ReproEndo said:

I do not accept that the fasting window is a minor inconvenience.

Adding the part of the answer the thread has not reached. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Following on from SallyK_inj — and this may be the naive question:

Whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong?

Closing the loop on my own question.

Follow-up: moving the tablet to the moment I wake, before anything else, was the whole fix. The dose never changed.